Eva Šimková

Medicine · Health Sciences

25h-index2.9kcitations96works6.32yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Kidney Stones and Urolithiasis Treatments(17), Education, Psychology, and Social Research(10), Renal Diseases and Glomerulopathies(9), Porphyrin Metabolism and Disorders(9), Biomedical Research and Pathophysiology(8)

Publications95 total

Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial
American Journal of Kidney Diseases·2025· 4 citedOpen Access
365.11: Pediatric kidney transplantation in Dubai. Outcomes and challenges.
Transplantation·2024· 1 cited
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial
Kidney International Reports·2024· 14 citedOpen Access
Environmental Education of Tourists for Sustainable Tourism Development
Czech Journal of Tourism·2023· 10 citedOpen Access
Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial
Journal of the American Society of Nephrology·2023· 1 cited
MP10-01 EFFICACY AND SAFETY OF LUMASIRAN IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1: 36-MONTH ANALYSIS OF THE ILLUMINATE-A TRIAL
The Journal of Urology·2023
Relapsing and refractory peritoneal dialysis peritonitis caused by Corynebacterium amycolatum
Pediatric Nephrology·2022· 7 citedOpen Access
Lumasiran for Patients With Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-Month Analysis of the Phase 3 ILLUMINATE-C Trial
Journal of the American Society of Nephrology·2022
Lumasiran chez les patients atteints d’hyperoxalurie primaire de type 1 (HP1) avec une fonction rénale altérée : données de l’analyse à 6 mois de l’essai de phase 3 ILLUMINATE-C
Néphrologie & Thérapeutique·2022
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial
American Journal of Kidney Diseases·2022· 79 citedOpen Access
Knowledge Management and Knowledge Transfer in a Tourism Destination
Hradec Economic Days ...·2022Open Access
FC070: Lumasiran for Patients with Primary Hyperoxaluria Type 1 with Impaired Kidney Function: Data from the 6-Month Analysis of the Phase 3 Illuminate-C Trial
Nephrology Dialysis Transplantation·2022
PD05-03 EFFICACY AND SAFETY OF LUMASIRAN IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1: 24-MONTH ANALYSIS OF THE ILLUMINATE-A TRIAL
The Journal of Urology·2022
Evaluation of pathogenetic features of antibiotic-associated syndrome using a biological model
Infekcionnye bolezni·2022
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
Kidney International Reports·2021· 29 citedOpen Access
ILLUMINATE-C, a Single-Arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD Stages 3b-5, Including Those on Hemodialysis
Journal of the American Society of Nephrology·2021· 3 cited
Analyse à 12 mois d’ILLUMINATE-A, une étude de phase 3 du lumasiran : réduction durable de l’oxalate et des taux d’évènements de calculs rénaux dans l’hyperoxalurie primitive de type 1
Néphrologie & Thérapeutique·2021
Insula activity in resting-state differentiates bipolar from unipolar depression: a systematic review and meta-analysis
Scientific Reports·2021· 29 citedOpen Access
MP07-09 12-MONTH ANALYSIS OF ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN: SUSTAINED OXALATE LOWERING AND KIDNEY STONE EVENT RATES IN PRIMARY HYPEROXALURIA TYPE 1
The Journal of Urology·2021Open Access
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
New England Journal of Medicine·2021· 471 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Franz Schaefer(12), Yaacov Frishberg(9), Hadas Shasha‐Lavsky(9), Daniella Magen(9), Jaap W. Groothoff(9), John C. Lieske(9), John M. Gansner(8), Tomáš Seeman(8), Karel Vondrák(8), J Janda(8), J Kreisinger(7), Tracy L. McGregor(6), Jeffrey M. Saland(5), Shabbir H. Moochhala(5), Pavel Dvořák(5), Sander F. Garrelfs(4), Sally A. Hulton(4), Michael J. Koren(4), Georges Deschênes(4), David J. Sas(4)